Join the 'HIV Infection' group to help and get support from people like you. How it works
HIV Infection Blog
Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS
| Tweet |
U.S. Assistance to Africa Cut AIDS-Related Deaths: Study
Posted 12 days ago by Drugs.com
TUESDAY, May 15 – The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President's Emergency Plan for AIDS Relief, a new study indicates. The program reduced adults' risk of death from all causes by 16 percent to 20 percent during those four years, Stanford University School of Medicine researchers found. The researchers said this is the first study to show a decline in all-cause deaths related to the program. "We were surprised and impressed to find these mortality reductions," study author Dr. Eran Bendavid, an assistant professor of medicine at Stanford, said in a university news release. "While many assume that foreign aid works, most evaluations of aid suggest it does not work or even causes harm," Bendavid said. "Despite all the challenges to making aid work and to implementing HIV treatment in Africa, the benefits of the ... Read more
Related support groups: HIV Infection
People With HIV at Higher Odds of Sudden Cardiac Death
Posted 13 days ago by Drugs.com
MONDAY, May 14 – People with HIV/AIDS are four times more likely to die of sudden cardiac arrest than those in the general population, a new study finds. The findings held true even for people with well-controlled HIV, according to researchers from the University of California, San Francisco (UCSF). In sudden cardiac arrest, also referred to as sudden cardiac death, the heart suddenly and unexpectedly stops beating. The researchers looked at the health records of more than 2,800 HIV patients from April 2000 to August 2009. About 8 percent died during an average follow-up period of nearly four years. Cardiac-related events accounted for 15 percent of those deaths. Of those, 86 percent of the patients died of sudden cardiac death. When researchers accounted for age, race and other variables, people with HIV had more than four times the risk of experiencing sudden cardiac death compared ... Read more
Related support groups: HIV Infection
FDA Panel Seems to Back Pill to Help Prevent HIV
Posted 18 days ago by Drugs.com
WEDNESDAY, May 9 – An advisory panel to the U.S. Food and Drug Administration appears to support the use of the drug Truvada as a means to help prevent HIV infection in people at high risk. Those individuals might include highly sexually active gay or bisexual men, or the partners of people already infected with HIV, the virus that causes AIDS. The advisory panel is meeting Thursday to mull whether or not to recommend Truvada as a preventive agent. However, a report released by the FDA this week ahead of the meeting suggests the experts do believe the drug is safe and effective for this use. There are potential drawbacks to using the medication in this way, however. Truvada – which combines two HIV-fighting drugs, tenofovir (Viread) and emtricitabine (Emtriva) – is very expensive and may cause side effects. And although doctors can already prescribe it to people trying to avoid HIV ... Read more
Related support groups: HIV Infection, Truvada, Emtricitabine/Tenofovir
HIV Drug Tenofovir Safe During Pregnancy, Study Suggests
Posted 3 May 2012 by Drugs.com
THURSDAY, May 3 – The use of the anti-HIV drug tenofovir during pregnancy appears to be safe for infants, new research suggests. In combination with other anti-HIV drugs, tenofovir (Viread) is the first line of treatment for adults with HIV, the virus that causes AIDS. These findings should reassure pregnant women who are taking tenofovir, the researchers said. The study was conducted by the U.S. National Institutes of Health network because previous studies showed that laboratory animals exposed to tenofovir in the womb were smaller at birth than those that were not exposed to the drug. The new study included 2,000 infants born to HIV-positive mothers between 2003 and 2010 in the United States. Infants born to mothers who took tenofovir during pregnancy did not weigh less at birth and did not have shorter length than those born to women who did not take the drug. At 1 year of age, ... Read more
Related support groups: HIV Infection, Atripla, Truvada, Complera, Viread, Tenofovir, Emtricitabine/lopinavir/ritonavir/tenofovir, Emtricitabine/rilpivirine/tenofovir, Efavirenz/Emtricitabine/Tenofovir, Emtricitabine/nelfinavir/tenofovir, Emtricitabine/Tenofovir
Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear
Posted 2 May 2012 by Drugs.com
WEDNESDAY, May 2 – New research shows that gene therapy can have long-lasting effects on the immune cells of HIV patients – a promising sign – even though the specific treatment being studied did not eradicate the virus. This approach is one of several gene therapy strategies that are being investigated by scientists as possible ways to keep the AIDS virus from spreading in the blood. In this case, "people were treated by gene therapy and nothing bad happened. It was safe," said study co-author Frederic Bushman, a professor of microbiology at the University of Pennsylvania. In addition, he said, the treated immune cells managed to remain around for about a decade. "The general picture that emerges about genetic alterations to human immune cells is that they can persist for a long time if you do it right." The study appears in the May 2 issue of Science Translational Medicine. ... Read more
Related support groups: HIV Infection
Children Usually Excluded From Clinical Drug Trials: Study
Posted 30 Apr 2012 by Drugs.com
MONDAY, April 30 – Children are more likely than adults to suffer from a number of diseases, but few clinical trials are conducted to test new drugs in children with these conditions, researchers have found. In a new study, researchers looked at all clinical trials registered worldwide from 2006 to 2011 for drugs to treat these common conditions: asthma, migraine headaches, schizophrenia, depression, diarrheal illness, lower respiratory infection, malaria, bipolar disorder and HIV/AIDS. While children account for 60 percent of the patients with these conditions, only 12 percent of the clinical drug trials involved children, the investigators found. The gap was widest for conditions that are widespread in low- and middle-income countries. Clinical drug trials in children are important because youngsters often respond differently to medications than adults, the study authors pointed out ... Read more
Related support groups: Bipolar Disorder, Migraine, Asthma, Diarrhea, Schizophrenia, HIV Infection, Malaria
FDA Medwatch Alert: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions
Posted 26 Apr 2012 by Drugs.com
[UPDATED 04/26/2012] FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended. The findings of a drug-drug interaction study and clinical trial showed that co-administration increased of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood to increase. Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), and Kaletra (lopinavir/ritonavir). [Posted 02/09/2012] ISSUE: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis ( ... Read more
Related support groups: Hepatitis C, HIV Infection, Victrelis, Kaletra, Norvir Soft Gelatin, Norvir, Ritonavir, Reyataz, Atazanavir, Prezista, Boceprevir, Lopinavir/Ritonavir, Emtricitabine/lopinavir/ritonavir/tenofovir, Darunavir
HIV Prevention Pill Cost-Effective for High-Risk Men: Study
Posted 17 Apr 2012 by Drugs.com
TUESDAY, April 17 – A once-a-day pill to prevent HIV infection could significantly reduce the spread of the AIDS-causing virus, but would only be cost-effective if limited to men at very high risk for HIV infection, according to a new study. Stanford University researchers created an economic model to analyze the use of the combination drug tenofovir-emtricitabine (brand name Truvada). A clinical trial found that the drug reduced a person's risk of HIV infection by an average of 44 percent when taken daily. In some people, the drug reduced the risk by 73 percent. But the drug is expensive – $26 a day, or $10,000 a year. The economic model focused on men who have sex with men, a group that accounts for more than of the 56,000 new HIV infections a year in the United States, according to the U.S. Centers for Disease Control and Prevention. The researchers found that giving the pill to ... Read more
Related support groups: HIV Infection, Truvada, Emtricitabine/Tenofovir
HIV Prevention Pill Cost-Effective for High-Risk Men: Study
Posted 17 Apr 2012 by Drugs.com
TUESDAY, April 17 – A once-a-day pill to prevent HIV infection could significantly reduce the spread of the AIDS-causing virus, but would only be cost-effective if limited to men at very high risk for HIV infection, according to a new study. Stanford University researchers created an economic model to analyze the use of the combination drug tenofovir-emtricitabine (brand name Truvada). A clinical trial found that the drug reduced a person's risk of HIV infection by an average of 44 percent when taken daily. In some people, the drug reduced the risk by 73 percent. But the drug is expensive – $26 a day, or $10,000 a year. The economic model focused on men who have sex with men, a group that accounts for more than of the 56,000 new HIV infections a year in the United States, according to the U.S. Centers for Disease Control and Prevention. The researchers found that giving the pill to ... Read more
Related support groups: HIV Infection, Truvada, Emtricitabine/Tenofovir
HIV Raises Anal Cancer Risk in Women, Study Says
Posted 16 Apr 2012 by Drugs.com
MONDAY, April 16 – Women with HIV are at increased risk for anal cancer, a new study finds. Researchers at Montefiore Medical Center in New York City looked at 715 HIV-infected women and found that 10.5 percent had some form of anal disease and about one-third of those women had precancerous disease. "Anal cancer was widely associated with HIV-infected men who have sex with men. But now, this study reveals anal precancerous disease in a high proportion of women with HIV," Dr. Mark Einstein, director of clinical research in the division of gynecologic oncology and a professor at Albert Einstein College of Medicine, said in a Montefiore news release. The increased risk of anal cancer in HIV-infected women is likely because HIV is associated with human papillomavirus (HPV), which causes nearly all anal cancers, the researchers said. The study appears May 1 in the Journal of AIDS. The ... Read more
Related support groups: HIV Infection
Sex Education Efforts Lagging in Schools, CDC Says
Posted 5 Apr 2012 by Drugs.com
THURSDAY, April 5 – There's been little progress in recent years in boosting the number of American secondary schools that teach students how to prevent pregnancy and protect themselves against HIV and other sexually transmitted diseases (STDs). That's the finding from researchers at the U.S. Centers for Disease Control and Prevention who analyzed 2008 and 2010 data from 45 states taking part in biennial surveys of school health practices. The surveys assessed the percentage of schools in each state that teach specific topics related to HIV, STD and pregnancy prevention. The topics differ in middle schools and high schools, but generally include basic information on the transmission and diagnosis of HIV and other STDs, as well as pregnancy risk reduction. Condom use is one of the topics that's covered only in high schools, the CDC said. The surveys revealed few indications of progress ... Read more
Related support groups: HIV Infection, Sexually Transmitted Diseases
From a Failed Vaccine, New Insights Into Fighting HIV
Posted 4 Apr 2012 by Drugs.com
WEDNESDAY, April 4 – A new study offers insight into why an HIV vaccine failed to protect most people who received it, but it also points to promising new targets for future vaccine efforts. Scientists believe an HIV vaccine, designed to prevent infection with the virus that causes AIDS, is still several years away. Tests of experimental vaccines have largely been failures so far. Nevertheless, the prospect of a vaccine remains tantalizing because it could make a major dent in the spread of HIV and AIDS around the world. The new research "gives us a handle on how the immune system deals with the virus and is affected by a vaccine," said study lead author Dr. Barton Haynes, director at the Duke Human Vaccine Institute at Duke University in Durham, N.C. "It gives us clues and a firm direction to look into." The study is based on work by more than 100 scientists from 25 institutions, and ... Read more
Related support groups: HIV Infection, Vaccination and Prophlaxis
'Superinfected' Patients Give Clues to Fighting HIV
Posted 29 Mar 2012 by Drugs.com
THURSDAY, March 29 – A stronger immune response occurs in women who have been infected with two different strains of HIV by two different sexual partners than in women infected with one strain of HIV, a new study finds. This type of dual infection is called HIV "superinfection." The finding that a mixture of different HIV strains may be one way to trigger a more powerful immune system antibody response may prove useful in efforts to develop an HIV vaccine in the fight against AIDS, according to the researchers at the Fred Hutchinson Cancer Research Center in Seattle. The researchers tracked the immune activity of 12 superinfected women in Kenya for five years. Compared to singly infected women, the superinfected women had about 70 percent more neutralizing antibodies (agents the immune system uses to fight invaders) and their antibodies' ability to neutralize HIV was almost 50 percent ... Read more
Related support groups: HIV Infection
Early, Temporary HIV Treatment Can Postpone Long-Term Therapy
Posted 28 Mar 2012 by Drugs.com
WEDNESDAY, March 28 – Early, 24-week treatment for people newly infected with HIV can delay the need at a later date to start long-term treatment, according to a new study. The study included 168 newly infected HIV patients who were randomly selected to receive no treatment, 24 weeks of treatment with combined antiretroviral drugs or 60 weeks of the drugs. Compared to those who received no treatment, patients who received early antiretroviral drugs had a lower viral set point, which is the stable point reached in the amount of HIV in the blood after the immune system begins to make antibodies to fight the virus. The researchers also found that patients who received no early treatment started long-term antiretroviral therapy within 0.7 years, compared with 3 years for those who received 24 weeks of early therapy and 1.8 years for those who received 60 weeks of early therapy. The study ... Read more
Related support groups: HIV Infection
FDA Approves Intelence (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review
Posted 27 Mar 2012 by Drugs.com
Titusville, NJ (March 27, 2012) – Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved Intelence (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to Read more
Related support groups: HIV Infection, Intelence, Etravirine
Page: 1 2 3 ... Next (151 results)
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
Atripla, Truvada, Kaletra, Complera, Sandoglobulin, Gammagard, Combivir, Norvir, ritonavir, view more... Norvir Soft Gelatin, Viread, Lexiva, tenofovir, Fuzeon, Reyataz, Flebogamma, Trizivir, Epivir, nevirapine, efavirenz, Edurant, Prezista, Agenerase, Octagam, Carimune, Retrovir, didanosine, Polygam S/D, amprenavir, abacavir, Sustiva, atazanavir, Ziagen, Isentress, Intelence, lamivudine, indinavir, stavudine, nelfinavir, raltegravir, etravirine, zidovudine, Gammagard S/D, Gammaplex, Panglobulin NF, Selzentry, darunavir, abacavir/lamivudine/zidovudine, Venoglobulin-S 5%, abacavir/lamivudine, Epzicom, Venoglobulin-S 10%, Gamimune N 10%, Telzir, Panglobulin, Iveegam En, Privigen, Gamimune N 5%, Gammar-P IV, Gamimune, Zerit XR, Carimune NF, Viracept, zalcitabine, tipranavir, emtricitabine/lopinavir/ritonavir/tenofovir, emtricitabine/nelfinavir/tenofovir, emtricitabine/rilpivirine/tenofovir, rilpivirine, saquinavir, emtricitabine/tenofovir, immune globulin intravenous, fosamprenavir, lamivudine/zidovudine, lopinavir/ritonavir, maraviroc, Rescriptor, Videx, Fortovase, Viramune, Invirase, Zerit, Hivid, Aptivus, enfuvirtide, efavirenz/emtricitabine/tenofovir, Emtriva, Videx EC, Crixivan, Epivir-HBV, emtricitabine, delavirdine